Haemonetics (HAE)

• Market cap: $3.17B
• 1 day: -0.68%
• 5 days: 0.82%
• 1 month: -16.24%
• 3 months: -26.23%
• 6 months: -16.43%
• Year to date: -19.62%
• 1 year: -13.99%
• 5 years: -46.72%
• 10 years: 43.13%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

29% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 90

23% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 40

4.31% more ownership

Funds ownership: 108.5% [Q3] → 112.81% (+4.31%) [Q4]

2% more call options, than puts

Call options by funds: $42.5M | Put options by funds: $41.7M

1% less funds holding

Funds holding: 303 [Q3] → 301 (-2) [Q4]

1% less capital invested

Capital invested by funds: $4.46B [Q3] → $4.42B (-$37.2M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $95 51% upside
• Avg. target: $107 69% upside
• High target: $116 84% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Andrew Cooper 14% 1-year accuracy 2 / 14 met price target	82% upside $115	Strong Buy Reiterated	7 Feb 2025
JMP Securities David Turkaly 31% 1-year accuracy 8 / 26 met price target	59% upside $100	Market Outperform Maintained	7 Feb 2025
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target	71% upside $108	Buy Maintained	7 Feb 2025
Barrington Research Michael Petusky 55% 1-year accuracy 39 / 71 met price target	51% upside $95	Outperform Maintained	7 Feb 2025
JP Morgan Rohin Patel 0% 1-year accuracy 0 / 1 met price target	84% upside $116	Overweight Initiated	6 Dec 2024